The German drug company CG developed and sold Thalidomide that was used to alleviate morning sickness in pregnant women. Shortly after the drug was sold, between 5,000 and 7,000 infants were born with malformation of the limbs. What would the company have to prove in order to take advantage of the state-of-the art defence in s 142?